Jessica Jensen, MD
Internal Medicine · Corinth, MSNPI 1013402254
Payments from drug & device makers
Across 243 payments — averaging $14.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$576
- AbbVie$512
- Novo Nordisk$479
- Otsuka America Pharmaceutical, Inc.$401
- GSK$288
- Amgen$282
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,586100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 38 | $576 |
| AbbVie(2 entities) | 40 | $512 |
| Novo Nordisk | 37 | $479 |
| Otsuka America Pharmaceutical, Inc. | 19 | $401 |
| GSK | 23 | $288 |
| Amgen | 19 | $282 |
| Boehringer Ingelheim | 13 | $213 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $202 |
| Lilly USA, LLC | 8 | $128 |
| Johnson & Johnson | 7 | $105 |
| AstraZeneca | 4 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $53 |
| Ironwood Pharmaceuticals, Inc | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Vapotherm Inc | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Edwards Lifesciences | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Merck | 1 | $12 |
| Chiesi USA, Inc. | 1 | $11 |
How this compares
$3,586 in reported general payments places this provider in the 80th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 11 | $75,414 |
| OzempicSemaglutide | 49 | $74,877 |
| EliquisApixaban | 126 | $36,405 |
| FarxigaDapagliflozin Propanediol | 74 | $28,934 |
| RybelsusSemaglutide | 13 | $25,597 |
| JardianceEmpagliflozin | 42 | $21,991 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $15,041 |
| LinzessLinaclotide | 23 | $14,488 |
| MovantikNaloxegol Oxalate | 29 | $6,631 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,819 |
| DapagliflozinDapagliflozin Propanediol | 20 | $5,731 |
| MyrbetriqMirabegron | 15 | $4,854 |
| XareltoRivaroxaban | 13 | $4,094 |
| Gabapentin | 417 | $3,413 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 124 | $2,881 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $479 | $100,47462 claims |
| AbbVieRinvoq, Linzess, Synthroid | $512 | $91,67653 claims |
| PfizerEliquis | $576 | $36,405126 claims |
| AstraZenecaFarxiga | $60 | $28,93474 claims |
| Boehringer IngelheimJardiance | $213 | $21,99142 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $288 | $20,86035 claims |
| Johnson & JohnsonXarelto | $105 | $4,09413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Corinth
- Paul VolanskyCorinth$15K
- Timothy NoyesCorinth$14K
- Sophia ThangCorinth$12K
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.